Compare · ARGX vs ATYR
ARGX vs ATYR
Side-by-side comparison of argenx SE (ARGX) and aTyr Pharma Inc. (ATYR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and ATYR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.51B, about 1165.1x ATYR ($45.9M).
- Over the past year, ARGX is up 49.9% and ATYR is down 91.3% - ARGX leads by 141.2 points.
- ARGX has been more active in the news (5 items in the past 4 weeks vs 4 for ATYR).
- ARGX has more recent analyst coverage (25 ratings vs 9 for ATYR).
- Company
- argenx SE
- aTyr Pharma Inc.
- Price
- $861.72-2.59%
- $0.47+3.04%
- Market cap
- $53.51B
- $45.9M
- 1M return
- +5.95%
- -50.91%
- 1Y return
- +49.88%
- -91.32%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2015
- News (4w)
- 5
- 4
- Recent ratings
- 25
- 9
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest ATYR
- aTyr Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Amendment: SEC Form SCHEDULE 13G/A filed by aTyr Pharma Inc.
- aTyr Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Schimmel Paul bought $49,630 worth of shares (100,000 units at $0.50) (SEC Form 4)
- SEC Form 10-Q filed by aTyr Pharma Inc.
- aTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
- SEC Form 4 filed by Director Coughlin Timothy
- SEC Form 4 filed by Director Benevich Eric
- SEC Form 4 filed by Director Gross Jane A